Tetrahydrocurcumin compositions, methods of making, and methods of using the same
US-12115138-B2 · Oct 15, 2024 · US
US10828277B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10828277-B2 |
| Application number | US-201515540002-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 18, 2015 |
| Priority date | Feb 16, 2015 |
| Publication date | Nov 10, 2020 |
| Grant date | Nov 10, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a centration of 2-30 g/L and vitamin C having a concentration of 1-14.3 g/L. The antioxidant complex provided in the present invention can effectively reduce the number of somatic cells in a diary cow and improve milk quality.
Opening claim text (preview).
What is claimed is: 1. A method of improving milk quality by administering an antioxidant preparation to a dairy cow with a somatic cell count greater than 100,000/mL for reducing the number of somatic cells in the dairy cow, characterized in that the preparation is in a form of an injection and comprises a combination of purified melatonin and vitamin C as active components, wherein four injections are administered at a neck of the dairy cow on four sequential days, wherein the administration comprises injecting 2 mL of the preparation to the dairy cow, wherein the concentration of the purified melatonin in the preparation is 1-23.2 g/L and the concentration of the vitamin C in the preparation is 1-14.3 g/L. 2. The method according to claim 1 , wherein concentration of the purified melatonin is 2.32 g/L. 3. The method according to claim 1 , wherein concentration of the vitamin C is 8.8 g/L. 4. The method according to claim 1 , wherein the antioxidant preparation is produced by a method comprising dissolving vitamin C in 75% ethanol solution followed by addition of melatonin, the operation process being carried out in dark. 5. The method according to claim 1 , wherein the concentration of the purified melatonin in the preparation is 2.32 g/L and the concentration of the vitamin C in the preparation is 8.8 g/L.
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title
Organic adjuvants · CPC title
from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.